カテゴリ： GlobalData, アメリカ, 企業調査

Illumina Inc (ILMN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Illumina Inc (ILMN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8013838
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：145
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Illumina, Inc. (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, the US.

Illumina Inc (ILMN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Illumina Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Illumina Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Illumina Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Illumina Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Illumina Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Illumina Inc, Medical Equipment, Deal Details 16
Venture Financing 16
SerImmune Raises USD8 Million in Venture Financing 16
Human Longevity Raises USD220 Million in Series B Financing Round 17
Grail Bio Raises USD100 Million in Series A Financing 18
Baebies Raises USD13 Million in Financing Round 19
Oxford Nanopore Raises US$64 Million In Venture Financing 20
GenoLogics Life Sciences Software Secures US$8 Million In Venture Financing 22
Genologics Life Sciences Secures US$5.1 Million In Series D Venture Financing 23
Oxford Nanopore Technologies Raises US$41 Million In Financing Round 24
Partnerships 26
Illumina Enters Into Licensing Agreement With Quest Diagnostics 26
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 27
Illumina Enters into Agreement with Pillar Biosciences 28
Hamilton Robotics Partners with Illumina 29
Lucigen Enters into Distribution Agreement with Illumina 30
Kailos Genetics Enters into Co-Marketing Agreement with Illumina 31
Analytik Jena Enters into Co-Development Agreement with Illumina 32
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 33
Invivoscribe Tech Enters into Agreement with Illumina 34
IBM Watson Health Enters into Agreement with Illumina 35
Koninklijke Philips Enters into Agreement with Illumina 36
Illumina Enters into Agreement with Mayo Clinic 37
Q2 Solutions Enters into Co-Development Agreement with Illumina 38
Illumina Enters into Agreement with FlowJo 39
Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 40
MolecularMD Enters into Agreement with Illumina 41
ArcherDX Enters into Co-Development Agreement with Illumina 42
Genomics England Partners with Illumina 43
Bio-Rad Laboratories Enters into Partnership with Illumina 44
Novogene Enters into Co-Development Agreement with Illumina 45
Almac Diagnostics Enters into Agreement with Illumina 46
Asuragen to Enter into Agreement with Illumina 47
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 48
Merck Serono Enters into Co- Development Agreement with Illumina 49
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 50
BioMerieux Enters into Co-Development Agreement with Illumina 51
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 52
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 53
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 54
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 55
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 56
Pathogenica Enters Into Co-Marketing Agreement With Illumina 57
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 58
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 59
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 60
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 61
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 62
GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 63
Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center 64
NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute 65
Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 66
Olerup SSP Enters Into Distribution Agreement With Conexio Genomics 67
Debt Offering 68
Illumina Raises USD550 Million in Private Placement of Notes Due 2019 68
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 69
Illumina Completes Private Placement Of 0.25% Convertible Senior Notes Due 2016 For US$800 Million 70
Asset Transactions 71
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 71
Pathway Genomics Acquires MiSeqDx From Illumina 72
Novogene Acquires HiSeq X Ten Sequencing System From Illumina 73
Acquisition 74
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 74
Illumina Acquires Conexio Genomics 75
Illumina Acquires Myraqa, In-Vitro Diagnostics Company 76
Illumina Acquires NextBio, Clinical and Genomic Informatics Company 77
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million 78
Illumina Acquires Advanced Liquid Logic 79
Illumina Completes Acquisition Of Verinata Health, In-Vitro Diagnostics Company, For Up To US$450 Million 80
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 82
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 83
Illumina Acquires Epicentre Biotechnologies 84
Illumina Inc – Key Competitors 85
Illumina Inc – Key Employees 86
Illumina Inc – Locations And Subsidiaries 87
Head Office 87
Other Locations & Subsidiaries 87
Joint Venture 89
Recent Developments 90
Strategy And Business Planning 90
Dec 01, 2016: Illumina Launches iHope Program to Identify Causes of Undiagnosed Genetic Diseases in Children 90
Jan 10, 2016: Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening 91
Financial Announcements 92
Oct 24, 2017: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017 92
Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 93
Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 94
Apr 25, 2017: Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 95
Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 96
Nov 01, 2016: Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016 98
Oct 10, 2016: Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016 99
Jul 26, 2016: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016 100
May 03, 2016: Illumina Reports Financial Results for First Quarter of Fiscal Year 2016 101
Apr 18, 2016: Illumina Announces Preliminary Revenue for First Quarter of Fiscal Year 2016 102
Feb 02, 2016: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015 103
Corporate Communications 105
Nov 08, 2017: Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare 105
May 22, 2017: Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role 106
Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 107
Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 108
Jan 03, 2017: Illumina Taps Garret Hampton, One of the World’s Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 109
Dec 20, 2016: Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team 110
Dec 07, 2016: Illumina appoints senior vice president and CFO 111
Dec 07, 2016: Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer 112
Jul 28, 2016: Illumina Names Philip W. Schiller to its Board of Directors 113
Jun 02, 2016: Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa 114
Mar 07, 2016: Jay Flatley to Assume Role of Executive Chairman of the Board of Directors of Illumina; Francis deSouza Appointed President and CEO 115
Jan 28, 2016: Illumina Appoints Dr. Frances Arnold to Its Board of Directors 116
Legal and Regulatory 117
Jul 03, 2017: Premaitha Health Litigation Update 117
Jul 07, 2016: Enzo Biochem’s Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina 118
Jul 04, 2016: Premaitha Health: Progress on anti-trust objections to litigation 119
Feb 23, 2016: Illumina Sues Oxford Nanopore for Patent Infringement 120
Jan 26, 2016: Premaitha Health: Update on UK Litigation Timing 121
Jan 07, 2016: Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT 122
Product News 123
Jul 13, 2017: World-leading Cancer Researchers First in UK to Receive Novaseq – The Latest Genome Sequencing Technology 123
Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 125
Jan 09, 2017: Illumina Introduces the NovaSeq Series—a New Architecture Designed to Usher in the $100 Genome 126
Nov 07, 2016: Illumina Launches TruSight Tumor 170 127
Oct 20, 2016: Illumina Contributes to ClinVar Database 128
May 09, 2016: Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders 129
Apr 05, 2016: Illumina Introduces BaseSpace Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs 131
02/24/2016: Illumina Applies CE Mark to VeriSeq NIPT Analysis Software 132
Jan 11, 2016: Illumina Extends Genomics Portfolio 133
Other Significant Developments 134
Jun 26, 2017: Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer 134
Jun 01, 2017: Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide 135
Apr 20, 2017: Personalis Orders Ten Illumina NovaSeq 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing 137
Apr 10, 2017: CloudHealth Genomics Makes China’s First Sequencing Data Available Using Illumina’s NovaSeq 6000 138
Apr 03, 2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC 139
Apr 03, 2017: Novogene Adds 25 Illumina NovaSeq Sequencers 140
Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance 141
Jun 16, 2016: Illumina Announces Initial Customer Orders for the Global Screening Array 142
Jun 06, 2016: ArcherDX Partners with Illumina to Bring Leading Fusion Oncology Assays to Global Markets 143
Appendix 144
Methodology 144
About GlobalData 144
Contact Us 144
Disclaimer 144

List of Tables
Illumina Inc, Medical Equipment, Key Facts, 2016 2
Illumina Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Illumina Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 9
Illumina Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 10
Illumina Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 11
Illumina Inc, Deals By Market, 2011 to YTD 2017 12
Illumina Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 13
SerImmune Raises USD8 Million in Venture Financing 17
Human Longevity Raises USD220 Million in Series B Financing Round 18
Grail Bio Raises USD100 Million in Series A Financing 19
Baebies Raises USD13 Million in Financing Round 20
Oxford Nanopore Raises US$64 Million In Venture Financing 21
GenoLogics Life Sciences Software Secures US$8 Million In Venture Financing 23
Genologics Life Sciences Secures US$5.1 Million In Series D Venture Financing 24
Oxford Nanopore Technologies Raises US$41 Million In Financing Round 25
Illumina Enters Into Licensing Agreement With Quest Diagnostics 27
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS 28
Illumina Enters into Agreement with Pillar Biosciences 29
Hamilton Robotics Partners with Illumina 30
Lucigen Enters into Distribution Agreement with Illumina 31
Kailos Genetics Enters into Co-Marketing Agreement with Illumina 32
Analytik Jena Enters into Co-Development Agreement with Illumina 33
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 34
Invivoscribe Tech Enters into Agreement with Illumina 35
IBM Watson Health Enters into Agreement with Illumina 36
Koninklijke Philips Enters into Agreement with Illumina 37
Illumina Enters into Agreement with Mayo Clinic 38
Q2 Solutions Enters into Co-Development Agreement with Illumina 39
Illumina Enters into Agreement with FlowJo 40
Personal Genome Diagnostics Enters into Co-Development Agreement with Illumina 41
MolecularMD Enters into Agreement with Illumina 42
ArcherDX Enters into Co-Development Agreement with Illumina 43
Genomics England Partners with Illumina 44
Bio-Rad Laboratories Enters into Partnership with Illumina 45
Novogene Enters into Co-Development Agreement with Illumina 46
Almac Diagnostics Enters into Agreement with Illumina 47
Asuragen to Enter into Agreement with Illumina 48
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology 49
Merck Serono Enters into Co- Development Agreement with Illumina 50
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 51
BioMerieux Enters into Co-Development Agreement with Illumina 52
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit 53
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 54
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 55
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 56
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 57
Pathogenica Enters Into Co-Marketing Agreement With Illumina 58
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics 59
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools 60
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 61
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 62
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 63
GenMark Diagnostics Enters Into Co-Development Agreement With Advanced Liquid Logic For Integrated Diagnostic Platform 64
Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center 65
NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute 66
Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 67
Olerup SSP Enters Into Distribution Agreement With Conexio Genomics 68
Illumina Raises USD550 Million in Private Placement of Notes Due 2019 69
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021 70
Illumina Completes Private Placement Of 0.25% Convertible Senior Notes Due 2016 For US$800 Million 71
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 72
Pathway Genomics Acquires MiSeqDx From Illumina 73
Novogene Acquires HiSeq X Ten Sequencing System From Illumina 74
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 75
Illumina Acquires Conexio Genomics 76
Illumina Acquires Myraqa, In-Vitro Diagnostics Company 77
Illumina Acquires NextBio, Clinical and Genomic Informatics Company 78
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million 79
Illumina Acquires Advanced Liquid Logic 80
Illumina Completes Acquisition Of Verinata Health, In-Vitro Diagnostics Company, For Up To US$450 Million 81
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer 83
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions 84
Illumina Acquires Epicentre Biotechnologies 85
Illumina Inc, Key Competitors 86
Illumina Inc, Key Employees 87
Illumina Inc, Other Locations 88
Illumina Inc, Subsidiaries 88
Illumina Inc, Joint Venture 90

★海外企業調査レポート[Illumina Inc (ILMN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • The Nassau Companies of New York：企業の戦略的SWOT分析
    The Nassau Companies of New York - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • AGC Inc (5201)：企業の財務・戦略的SWOT分析
    AGC Inc (5201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • New Brunswick Power Corporation：企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Arch Therapeutics Inc (ARTH)：医療機器：M&Aディール及び事業提携情報
    Summary Arch Therapeutics Inc (Arch Therapeutics) is a medical device company that develops self-assembling barrier technologies to improve interventional wound care outcomes. The company offers hemostasis and sealant products to seal and protect leaking and bleeding tissue. It provides intervention …
  • Morinaga & Co., Ltd. (2201)：企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ADNOC Distribution (ADNOCDIST)：石油・ガス：M&Aディール及び事業提携情報
    Summary ADNOC Distribution, a subsidiary of Abu Dhabi National Oil Co (ADNOC), markets and distributes petroleum products, natural gas and other products. The company mainly operates in the retail transportation fuels, wholesale fuels, and forecourt convenience store markets in Abu Dhabi and the nor …
  • Butler National Corporation：企業の戦略・SWOT・財務情報
    Butler National Corporation - Strategy, SWOT and Corporate Finance Report Summary Butler National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • El Puerto de Liverpool SAB de CV：企業の戦略・SWOT・財務情報
    El Puerto de Liverpool SAB de CV - Strategy, SWOT and Corporate Finance Report Summary El Puerto de Liverpool SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Kansai Nerolac Paints Ltd：企業の戦略・SWOT・財務情報
    Kansai Nerolac Paints Ltd - Strategy, SWOT and Corporate Finance Report Summary Kansai Nerolac Paints Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ONEOK Partners LP (OKS)-石油・ガス分野：企業M&A・提携分析
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • Rad Source Technologies Inc：企業の戦略的SWOT分析
    Rad Source Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Faroe Petroleum plc (FPM)：企業の財務・戦略的SWOT分析
    Summary Faroe Petroleum Plc (Faroe Petroleum) is an oil and gas company that concentrates on exploration, appraisal, development and production opportunities. The company has its exploration and development assets in the UK. Its operations portfolio consists of exploration, appraisal, development an …
  • Lojas Renner S.A.：企業の戦略・SWOT・財務情報
    Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report Summary Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • EMS SA：企業の戦略的SWOT分析
    EMS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Schneider Electric (Australia) Pty Ltd：企業の戦略的SWOT分析
    Schneider Electric (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • iX Biopharma Ltd (42C)：企業の財務・戦略的SWOT分析
    Summary iX Biopharma Ltd (iX Biopharma) is a pharmaceutical company that provides that offers drug delivery and formulation. The company's pipeline product portfolio includes development of drugs for various indications such as opioid-sparing for acute, severe and chronic pain; male erectile dysfunc …
  • Oxiteno SA Industria E Comercio：企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Cognition Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platf …
  • Center For Diagnostic Imaging Inc-医療機器分野：企業M&A・提携分析
    Summary Center For Diagnostic Imaging Inc (CDI), a subsidiary of InSight Health Services Holdings Corp is a healthcare center that patient care services. The center offers upright MRI, diagnostic breast imaging exams, breast biopsies, open CDI vascular care, open upright MRI, nuclear medicine, ultra …
  • NATS Holdings Limited：企業の戦略・SWOT・財務情報
    NATS Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary NATS Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆